Compounds and Combinations Thereof for Treating Neurological and Psychiatric Conditions

USPTO published patent application US20260097006A1 for compounds and combinations containing dextromethorphan intended for treating neurological and psychiatric conditions, particularly depression. The application discloses oral administration methods typically combined with antidepressants like bupropion.\n\nPharmaceutical companies developing or manufacturing dextromethorphan-based therapeutics should review this publication for potential freedom-to-operate implications. The patent application may eventually grant exclusive rights to the disclosed combinations and methods, which could affect existing or planned product development. Monitoring patent prosecution is advisable for companies in this therapeutic space.